Generic Prevduo Availability
Last updated on Sep 11, 2024.
Prevduo is a brand name of glycopyrrolate/neostigmine, approved by the FDA in the following formulation(s):
PREVDUO (glycopyrrolate; neostigmine methylsulfate - solution;intravenous)
-
Manufacturer: AZURITY
Approval date: February 23, 2023
Strength(s): 0.6MG/3ML (0.2MG/ML);3MG/3ML (1MG/ML) [RLD]
Has a generic version of Prevduo been approved?
No. There is currently no therapeutically equivalent version of Prevduo available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Prevduo. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate
Patent 10,456,354
Issued: October 29, 2019
Inventor(s): Bhise Rahul Dhulaji & Singh Ajay Kumar & Mahadik Mahadeo Vasant & Dubewar Ashish Anilrao & Reddy Molugu Prashanth
Assignee(s): SLAYBACK PHARMA LLCThe present invention provides stable, ready-to-use injectable pharmaceutical compositions, comprising the combination of neostigmine, glycopyrrolate, a stabilizing amount of one or more aminopolycarboxylic acids, and a pharmaceutically acceptable liquid vehicle. Other aspects of the invention relate to methods for making such compositions and methods of using such compositions for reversing the effects of non-depolarizing neuromuscular blocking agents. Preferably, the composition comprises neostigmine methylsulfate, glycopyrronium bromide, ethylenediaminetetraacetic acid (EDTA) and a pharmaceutically acceptable liquid vehicle, and is provided in a pre-filled, ready-to-use sealed container, such as a pre-filled syringe, suitable for intravenous administration.
Patent expiration dates:
- October 25, 2038✓
- October 25, 2038
-
Patent 11,110,054
Patent expiration dates:
- October 25, 2038✓
- October 25, 2038
-
Patent 11,938,217
Patent expiration dates:
- October 25, 2038✓
- October 25, 2038
More about Prevduo (glycopyrrolate / neostigmine)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- Drug class: antidotes
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
